Aug, 2020 - By CMI
Over the last couple of decades, cancer has emerged as one of the biggest threats to mankind, with a staggering 14.1 million cases as of 2012. Breast cancer is the second-most prevalent cancer, with around 1.7 million cases registered in 2012 alone. Apart from the increasing incidence of the disease, awareness about breast cancer has increased manifold thanks to the much-hyped double mastectomy that popular actress and humanitarian, Angelina Jolie underwent. Her rather bold decision was a consequence of the discovery of a genetic mutation that she inherited, which increased her chances of acquiring breast cancer to 87%. The discovery was fruitful mainly due to early detection through breast ultrasound scanning. This, in turn, has led to a rapid surge in curiosity among the populace, characterized by the realization that early diagnosis is vital in order to ensure effective treatment.
According to the report titled ‘Global Automated Breast Ultrasound Systems (ABUS) Market – By Product Type (Prone And Supine), By End-User (Hospitals, Ambulatory Surgical Units, And Diagnostic Center), By Application (Screening And Pre-Operative Evaluation), By Geography – Trends And Forecast To 2024’ published by Coherent Market Insights, the market for Automated Breast Ultrasound Systems (ABUS) is expected to surpass US$ 1.6 billion by the end of 2024, expanding at a robust CAGR of 21.6% during 2016–2024.
The ultrasound system to detect breast cancer is a painless noninvasive 3D technology that is absolutely safe and free from radiation. This procedure is exclusively crafted for thorough breast imaging. It acquires multiple 3D ultrasound images of the entire breast using a scanner with a broadband transducer in a completely automated manner.
Breast cancer is the most prevalent cancer among women worldwide, with around 2 million new cases registered each year. This drastic increase in incidence, in turn, necessitates a rise in the adoption of related diagnostic devices.
GE Healthcare, Koninklijke Philips, Hitachi, SonoCiné, Inc., and Siemens AG are among the leading players in the automated breast ultrasound systems market. On the basis of application, the market is segmented into hospitals and diagnostic imaging. These systems, involving high capital investment are mainly installed in large hospitals and thus, the segment accounts for the largest market revenue share. The segment is expected to further gain traction through 2020.
Major players in the market are focusing on entering into strategic partnerships in order to reduce capital investment especially related to R&D activities to introduce technologically advanced products in the market. Furthermore, significant investment in strengthening the healthcare infrastructure in developing countries and the replacement of existing equipment with advanced systems in developed countries is expected to create a favorable environment for the automated breast ultrasound systems market in the near future. The market is expected to gain further impetus by initiatives of various health organizations across the globe, endorsed by celebrities.